1
|
Sardarabadi H, Darvishi MH, Zohrab F, Javadi H. Nanophytomedicine: A promising practical approach in phytotherapy. Phytother Res 2024; 38:3607-3644. [PMID: 38725270 DOI: 10.1002/ptr.8230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2023] [Revised: 04/19/2024] [Accepted: 04/22/2024] [Indexed: 07/12/2024]
Abstract
The long and rich history of herbal therapeutic nutrients is fascinating. It is incredible to think about how ancient civilizations used plants and herbs to treat various ailments and diseases. One group of bioactive phytochemicals that has gained significant attention recently is dietary polyphenols. These compounds are commonly found in a variety of fruits, vegetables, spices, nuts, drinks, legumes, and grains. Despite their incredible therapeutic properties, one challenge with polyphenols is their poor water solubility, stability, and bioavailability. This means that they are not easily absorbed by the body when consumed in essential diets. Because of structural complexity, polyphenols with high molecular weight cannot be absorbed in the small intestine and after arriving in the colon, they are metabolized by gut microbiota. However, researchers are constantly working on finding solutions to enhance the bioavailability and absorption of these compounds. This study aims to address this issue by applying nanotechnology approaches to overcome the challenges of the therapeutic application of dietary polyphenols. This combination of nanotechnology and phytochemicals could cause a completely new field called nanophytomedicine or herbal nanomedicine.
Collapse
Affiliation(s)
- Hadi Sardarabadi
- Department of Physiology and Pharmacology, School of Medicine, Qom University of Medical Sciences, Qom, Iran
| | - Mohammad Hasan Darvishi
- Nanobiotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
| | - Fatemeh Zohrab
- Department of Medical Science, Qom Branch, Islamic Azad University, Qom, Iran
| | - Hamidreza Javadi
- Nanobiotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
| |
Collapse
|
2
|
Applications of Perilla frutescens Extracts in Clinical Practice. Antioxidants (Basel) 2023; 12:antiox12030727. [PMID: 36978975 PMCID: PMC10045045 DOI: 10.3390/antiox12030727] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2023] [Revised: 03/11/2023] [Accepted: 03/14/2023] [Indexed: 03/18/2023] Open
Abstract
(1) Background: Perilla frutescens (L.) Britt. is an important pharmaceutical crop that remains a focus point for researchers worldwide due to its complex phytochemical constituents, medicinal effects, and nutraceutical properties. The literature data are based on animal and cell culture studies, so the clinical evidence for the therapeutic effects is poorly outlined. The aim of this review was to provide an updated and thorough understanding of Perilla frutescens applications in clinical practice using data derived from human studies, and to outline the potential directions and perspectives for further studies on this crop. (2) Methods: Medline, Embase, and Cochrane databases were used to find relevant studies. All interventional studies that evaluated the effect of Perilla frutescens in human subjects were assessed. (3) Results: The main perspectives that can be contoured from the presented literature evaluation are an important clinical effect of Perilla frutescens extracts on allergic rhinoconjuctivitis, especially in young populations, a potent hypolipemiant effect that, in conjunction with increased serum biological antioxidant potential, determines significant improvements in cognitive function and a wide variety of miscellaneous clinical effects that need further exploration. (4) Conclusions: Supplementary research is needed in order to demonstrate the therapeutic effects of Perilla frutescens in controlled clinical settings.
Collapse
|
3
|
Jaragh-Alhadad L, Behbehani H, Karnik S. Cancer targeted drug delivery using active low-density lipoprotein nanoparticles encapsulated pyrimidines heterocyclic anticancer agents as microtubule inhibitors. Drug Deliv 2022; 29:2759-2772. [PMID: 36029014 PMCID: PMC9427048 DOI: 10.1080/10717544.2022.2117435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Recently, nanomedicine had the potential to increase the delivery of active compounds to specific cell sites. Nano-LDL particles are recognized as an excellent active nano-platform for cancer-targeted delivery. Loading of therapeutic agents into nano-LDL particles achieved by surface loading, core loading, and apolipoprotein-B100 interaction. Therefore, loading nano-LDL particles’ core with pyrimidine heterocyclic anticancer agents will increase cancer cytotoxic activity targeting tubulin protein. First, by mimicking the native LDL particle's metabolic pathway, and second the agent’s chemical functional groups like the native amino acids cytosine and thymine structures will not be recognized as a foreign entity from the cell’s immune system. Nano-LDL particles will internalize through LDL-receptors endocytosis and transport the anticancer agent into the middle of the cancer cell, reducing its side effects on other healthy cells. Generally, the data revealed that pyrimidine heterocyclic anticancer agents’ size is at the nano level. Agents’ morphological examination showed nanofibers, thin sheets, clusters, and rod-like structures. LDL particles’ size became bigger after loading with pyrimidine heterocyclic anticancer agents and ranged between 121.6 and 1045 nm. Then, particles were tested for their cytotoxicity against breast (MDA468) and prostate (DU145) cancer cell lines as surrogate models with dose-response study 10, 5, 1 µM. The IC50 values of the agents against DU145 and MDA468 possessed cell growth inhibition even at the 1 µM concentration ranges of 3.88 ± 1.05 µM and 3.39 ± 0.97 µM, respectively. In sum, nano-LDL particles proved their efficiency as active drug delivery vehicles to target tubulin in cancer cells.
Collapse
Affiliation(s)
- Laila Jaragh-Alhadad
- Department of Chemistry, Faculty of Science, Kuwait University, Safat, Kuwait.,Cardiovascular and Metabolic Sciences Department, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA
| | - Haider Behbehani
- Department of Chemistry, Faculty of Science, Kuwait University, Safat, Kuwait
| | - Sadashiva Karnik
- Cardiovascular and Metabolic Sciences Department, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA.,Cleveland Clinic Learner College of Medicine, Case Western Reserve University, Cleveland, OH, USA
| |
Collapse
|
4
|
Kalinowska M, Gołębiewska E, Świderski G, Męczyńska-Wielgosz S, Lewandowska H, Pietryczuk A, Cudowski A, Astel A, Świsłocka R, Samsonowicz M, Złowodzka AB, Priebe W, Lewandowski W. Plant-Derived and Dietary Hydroxybenzoic Acids-A Comprehensive Study of Structural, Anti-/Pro-Oxidant, Lipophilic, Antimicrobial, and Cytotoxic Activity in MDA-MB-231 and MCF-7 Cell Lines. Nutrients 2021; 13:nu13093107. [PMID: 34578985 PMCID: PMC8466373 DOI: 10.3390/nu13093107] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2021] [Revised: 09/01/2021] [Accepted: 09/02/2021] [Indexed: 11/22/2022] Open
Abstract
Seven derivatives of plant-derived hydroxybenzoic acid (HBA)—including 2,3-dihydroxybenzoic (2,3-DHB, pyrocatechuic), 2,4-dihydroxybenzoic (2,4-DHB, β-resorcylic), 2,5-dihydroxybenzoic (2,5-DHB, gentisic), 2,6-dihydroxybenzoic (2,6-DHB, γ-resorcylic acid), 3,4-dihydroxybenzoic (3,4-DHB, protocatechuic), 3,5-dihydroxybenzoic (3,5-DHB, α-resorcylic), and 3,4,5-trihydroxybenzoic (3,4,5-THB, gallic) acids—were studied for their structural and biological properties. Anti-/pro-oxidant properties were evaluated by using DPPH• (2,2-diphenyl-1-picrylhydrazyl), ABTS•+ (2,2-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid), FRAP (ferric-reducing antioxidant power), CUPRAC (cupric-reducing antioxidant power), and Trolox oxidation assays. Lipophilicity was estimated by means of experimental (HPLC) and theoretical methods. The antimicrobial activity against Escherichia coli (E. coli), Pseudomonas aeruginosa (P. aeruginosa), Staphylococcus aureus (S. aureus), Bacillus subtilis (B. subtilis), Salmonella enteritidis (S. enteritidis), and Candida albicans (C. albicans) was studied. The cytotoxicity of HBAs in MCF-7 and MDA-MB-231 cell lines was estimated. Moreover, the structure of HBAs was studied by means of experimental (FTIR, 1H, and 13C NMR) and quantum chemical DFT methods (the NBO and CHelpG charges, electrostatic potential maps, and electronic parameters based on the energy of HOMO and LUMO orbitals). The aromaticity of HBA was studied based on the calculated geometric and magnetic aromaticity indices (HOMA, Aj, BAC, I6, NICS). The biological activity of hydroxybenzoic acids was discussed in relation to their geometry, the electronic charge distribution in their molecules, their lipophilicity, and their acidity. Principal component analysis (PCA) was used in the statistical analysis of the obtained data and the discussion of the dependency between the structure and activity (SAR: structure–activity relationship) of HBAs. This work provides valuable information on the potential application of hydroxybenzoic acids as bioactive components in dietary supplements, functional foods, or even drugs.
Collapse
Affiliation(s)
- Monika Kalinowska
- Department of Chemistry, Biology and Biotechnology, Bialystok University of Technology, Wiejska 45E Street, 15-351 Bialystok, Poland; (E.G.); (G.Ś.); (R.Ś.); (M.S.)
- Correspondence:
| | - Ewelina Gołębiewska
- Department of Chemistry, Biology and Biotechnology, Bialystok University of Technology, Wiejska 45E Street, 15-351 Bialystok, Poland; (E.G.); (G.Ś.); (R.Ś.); (M.S.)
| | - Grzegorz Świderski
- Department of Chemistry, Biology and Biotechnology, Bialystok University of Technology, Wiejska 45E Street, 15-351 Bialystok, Poland; (E.G.); (G.Ś.); (R.Ś.); (M.S.)
| | - Sylwia Męczyńska-Wielgosz
- Institute of Nuclear Chemistry and Technology, 16 Dorodna Street, 03-195 Warsaw, Poland; (S.M.-W.); (H.L.)
| | - Hanna Lewandowska
- Institute of Nuclear Chemistry and Technology, 16 Dorodna Street, 03-195 Warsaw, Poland; (S.M.-W.); (H.L.)
| | - Anna Pietryczuk
- Department of Water Ecology, Faculty of Biology, University of Bialystok, Ciolkowskiego 1J Street, 15-245 Bialystok, Poland; (A.P.); (A.C.)
| | - Adam Cudowski
- Department of Water Ecology, Faculty of Biology, University of Bialystok, Ciolkowskiego 1J Street, 15-245 Bialystok, Poland; (A.P.); (A.C.)
| | - Aleksander Astel
- Environmental Chemistry Research Unit, Institute of Biology and Earth Sciences, Pomeranian University in Słupsk, Arciszewskiego 22a Street, 76-200 Słupsk, Poland;
| | - Renata Świsłocka
- Department of Chemistry, Biology and Biotechnology, Bialystok University of Technology, Wiejska 45E Street, 15-351 Bialystok, Poland; (E.G.); (G.Ś.); (R.Ś.); (M.S.)
| | - Mariola Samsonowicz
- Department of Chemistry, Biology and Biotechnology, Bialystok University of Technology, Wiejska 45E Street, 15-351 Bialystok, Poland; (E.G.); (G.Ś.); (R.Ś.); (M.S.)
| | - Anna Barbara Złowodzka
- Faculty of Chemistry, Warsaw University of Technology, Noakowskiego 3 Street, 00-664 Warszawa, Poland;
| | - Waldemar Priebe
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 1901 East Rd., Houston, TX 77054, USA;
| | - Włodzimierz Lewandowski
- Institute of Agricultural and Food Biotechnology—State Research Institute, Rakowiecka 36 Street, 02-532 Warsaw, Poland;
| |
Collapse
|